Comparison of nocturnal symptoms in advanced Parkinson&amp;rsquo;s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations

Xiang, Wei; Sun, Ya Qing; Teoh, Hui Chin

doi:10.2147/dddt.s160300

Cited by 20 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 , 5 Pramipexole, a dopamine receptor agonist, was approved for the treatment of early and late PD in the United States and Europe in 1998. 6 Through a neuroprotective effect, pramipexole delays levodopa-induced motor complications in early PD, controls motor symptoms, and relieves depression in PD patients. 7 A recent study demonstrated that inflammatory cytokines are abnormally expressed in patients with neurodegenerative diseases and are involved in disease development.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

et al. 2020

View full text Add to dashboard Cite

Purpose To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson’s disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. Basic Procedure In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks. Findings After treatment, scores from the Unified Parkinson’s Disease Rating Scales (1–3), the Hamilton Depression Scale, and the Parkinson’s Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels. Conclusion Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Firstly, the replacement of lost dopamine with dopaminergic drugs in 24 h is necessary for the management of motor symptoms alone – regardless of whether these occur nocturnally or during the daytime. Adjunctive medications [ 31 – 33 ], infusion systems such as DuoDopa (carbidopa/levodopa) [ 34 ], continuous dopamine delivery treatments like the transdermal rotigotine patch [ 35 – 39 ], and oral extended release versions of dopamine agents [ 40 , 41 ] have shown significant promise in ameliorating wearing-off effects and symptom fluctuations, in nocturnal as well as daytime symptoms. In a randomized, placebo-controlled study (the RECOVER trial, quality score, 93%), patients with unsatisfactory control of early morning motor symptoms were evaluated on the PDSS-2 and UPDRS III.…”

Section: Discussionmentioning

confidence: 99%

Social listening – revealing Parkinson’s disease over day and night

Zhang¹,

Meng²,

Li³

et al. 2021

BMC Neurol

View full text Add to dashboard Cite

Background Nocturnal symptoms in Parkinson’s disease are often treated after management of daytime manifestations. In order to better understand the unmet needs of nocturnal symptoms management, we analyzed the characteristics and burden of nocturnal symptoms from patients’ perspectives and explored their changes over time. Overall symptoms (occurring at day or night) were collected to compare whether the unmet needs related to nocturnal symptoms and to overall symptoms are different. Methods We used a Social Listening big-data technique to analyze large amounts of Parkinson’s disease symptoms in dialogues available from social media platforms in 2016 to 2018. These symptoms were classified as either overall symptoms or nocturnal symptoms. We used share of voice (SOV) of symptoms as a proportion of total dialogues per year to reflect the characteristics of symptoms. Negative sentiment score of symptoms was analyzed to find out their related burden. Results We found the SOV for overall motor symptoms was 79% and had not increased between 2016 and 2018 (79%, p = 0.5). The SOV for non-motor symptoms was 69% and had grown by 7% in 2018 (p < 0.01). The SOV for motor complications was 9% and had increased by 6% in 2018 (p < 0.01). The SOV of motor symptoms was larger than non-motor symptoms and motor complications (p < 0.01). The SOV of non-motor symptoms was larger than motor complications (p < 0.01). For nocturnal symptoms, 45% of the analyzed PD population reported nocturnal symptoms in 2018, growing by 6% (p < 0.01). The SOV for nocturnal-occurring motor symptoms was higher than most non-motor symptoms. However, non-motor symptoms had the higher increases and evoked higher negative sentiment regardless of whether they occurred during the day or night. For symptoms that can occur at either day or night, each nocturnal symptom was rated with a higher negative sentiment score than the same symptom during the day. Conclusions The growing SOV and the greater negative sentiment of nocturnal symptoms suggest management of nocturnal symptoms is an unmet need of patients. A greater emphasis on detecting and treating nocturnal symptoms with 24-h care is encouraged.

show abstract

“…A similar pattern of improvement of insomnia symptoms among individuals with advanced PD and insomnia symptoms (PDSS <90) was observed with the addition of pramipexole sustained release or immediate release (IR). 50 Although individuals experienced significant increases in the PDSS total, global sleep quality, and nocturnal motor symptoms subscales over time with either pramipexole formulation, individuals receiving the sustained release experienced larger (but nonsignificant) improvements over the IR.…”

Section: Treatments Of Insomnia In Pd Dopaminergic Medications For Inmentioning

confidence: 94%

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Wallace

Wohlgemuth

Trotti

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Insomnia is one of the most common nonmotor features of Parkinson's disease (PD). However, there are few practical guidelines for providers on how to best evaluate and treat this problem. Methods and Findings This review was developed to provide clinicians with a pragmatic approach to assessing and managing insomnia in PD. Recommendations were based on literature review and expert opinion. We addressed the following topics in this review: prevalence of insomnia in PD, sleep–wake mechanisms, theoretical models of insomnia, risk factors, assessment, pharmacologic and nonpharmacologic treatments. Insomnia treatment choices may be guided by PD severity, comorbidities, and patient preference. However, there is limited evidence supporting pharmacotherapy and nonpharmacologic treatments of insomnia in PD. Conclusions We provide a pragmatic algorithm for evaluating and treating insomnia in PD based on the literature and our clinical experience. We propose personalized insomnia treatment approaches based on age and other issues. Gaps in the existing literature and future directions in the treatment of insomnia in PD are also highlighted.

show abstract

Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations

Cited by 20 publications

References 33 publications

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

RETRACTED: Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels

Social listening – revealing Parkinson’s disease over day and night

Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review

Contact Info

Product

Resources

About